Track topics on Twitter Track topics that are important to you
P.O. Box 303
Phone: 46 (0)18 780 88 00
Fax: 46 (0)18 780 88 88
Edison Investment Research - Pharmaceutical & healthcare - Orexo: Orexo reported an operational quarter in line with guidance. Total revenues of SEK139.7m in Q118 represented an increase of about 10% ...
Edison Investment Research - Pharmaceutical & healthcare - Orexo: Yesterday Orexo announced the launch of Zubsolv in the EU by its partner Mundipharma, triggering a €3m (c SEK30.6m) milestone pay...
Orexo AB announces that its partner Mundipharma has initiated the launch of Zubsolv (buprenorphine and naloxone sublingual tablet), for use in the treatment of opioid dependence, in the EU.
(Logo: https://mma.prnewswire.com/media/707203/Orexo_Logo.jpg) It is estimated that there are approximately 1.3 million high-risk opioid users in Europe. Although estimates vary signifi...
Läkemedelsbolaget letar ny finanschef efter att Henrik Juuel beslutat lämna bolaget.
This is a phase II study in patients with seasonal allergic rhinitis (SAR) and will compare the effect versus placebo of two different oral doses of BLX-028914 in an allergen challenge mod...
We start by matching unmet patient needs with the unrealized potential in many existing compounds. We create novel pharmaceuticals, at lower development cost and risk, with shorter time to market. The...
We have published hundreds of Orexo AB news stories on BioPortfolio along with dozens of Orexo AB Clinical Trials and PubMed Articles about Orexo AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Orexo AB Companies in our database. You can also find out about relevant Orexo AB Drugs and Medications on this site too.